Crystal Zuzek

March 2014 Texas Medicine

April 2013 Texas Medicine

SUMMER 2023 Damon Schranz, DO, FACOFP 2023–2024 TOMA President 12 Combating Obesity Texas DOs weigh in on treatment strategies 16 Texas DOs Convene at COM 20 Growing TOMA TOMA/TXACOFP's Annual Convention meets for the first time ever at UIW-SOM TOMA's new president sees opportunities to add more DOs

Case study promoting the Texas Medical Association's medical liability advocacy and its appeal to physician members who are new to Texas

Case study highlighting the Texas Medical Association's benefits for employed physician members

Case study promoting the Texas Medical Association's advocacy efforts on behalf of academic physician members

Case study promoting the Texas Medical Association's medical practice setup services for physician members

This summer, future MBA candidates convened in seven cities across the U.S. for Forte’s first in-person MBA Forums since 2019. Hear from two women who joined us in New York and Los Angeles about their experiences exploring the MBA and connecting with top b-schools.

When Jennifer Chacón Salas decided to get into business consulting, her partner encouraged her to consider getting an MBA. For two-and-a-half years she’d been working in Costa Rica as a risk and advisory services manager for a U.S. company.
“I am a problem solver, and I love to work with people. I did a ton of research, talked to my mentors, and decided that it [business school] was the best way to gain the skills I need to make a career change,” she explains.
Eager to start he...

As part of its broader commitment to research on cardiovascular diseases, the NHLBI leads and supports research and programs on high blood pressure. The NHLBI has funded several studies and programs to help develop new treatments for high blood pressure, many of which focus on women’s health, lifestyle interventions, and health disparities. Current studies aim to prevent pregnancy complications and improve blood pressure among people in high-risk groups.

Today, no cure exists for cystic fibrosis. But for decades, NHLBI has led and supported research on the disease, and those efforts have brought about more and better treatment options. Cystic fibrosis is caused by mutations, or changes, in the gene that affects the cystic fibrosis transmembrane conductance regulator (CFTR) protein.